Logo Lanfrica

An open-label study assessing effectiveness, safety and compliance with fexinidazole in patients with human African Trypanosomiasis due to T.b. gambiense at any stage

Domaine:

healthcare
Créateur:
DNDi
Éditeur:
Viv
Hôte:avatar
Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.

Tags

Conditions: HATInterventions: Fexinidazole

Licenses

Study data may be accessed by completing a request form at https://vivli.org. It will then be reviewed according to the data contributor’s governance policy, see https://vivli.org/members/ourmembers/ for Vivli member’s review process. If approved, use of the data is governed by the data use agreement at https://vivli.org/resources/vivli-data-use-agreement/

Similaires

Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study

Vivli is an independent, non-profit organization that has developed a global data-sharing and analyt

Efficacy and safety of fexinidazole compared to nifurtimox-eflornithine combination therapy (NECT) in patients with late-stage Human African Trypanosomiasis (HAT) due to T.b. gambiense: pivotal, non-inferiority, multicentre, randomised, open-label study

Vivli is an independent, non-profit organization that has developed a global data-sharing and analyt

Efficacy and Safety of Fexinidazole in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Rhodesiense: a Multicentre, Open-label Clinical Trial

The ultimate goal of this study is to show that fexinidazole offers an alternative over the existing

Efficacy and safety of fexinidazole in children at least 6 years old and weighing over 20 kg with human African trypanosomiasis (HAT) due to T.b. gambiense: a prospective, multicentre, open study, plug-in to the pivotal study

Vivli is an independent, non-profit organization that has developed a global data-sharing and analyt

Efficacy and safety of fexinidazole in patients with Human African Trypanosomiasis (HAT) due to Trypanosoma brucei rhodesiense: a multicentre clinical trial

Vivli is an independent, non-profit organization that has developed a global data-sharing and analyt